{"id":55130,"date":"2023-12-20T08:08:10","date_gmt":"2023-12-20T08:08:10","guid":{"rendered":"https:\/\/medsname.com\/invokana-canagliflozin\/"},"modified":"2026-05-01T10:49:12","modified_gmt":"2026-05-01T10:49:12","slug":"invokana-canagliflozin","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/invokana-canagliflozin\/","title":{"rendered":"Invokana (Canagliflozin)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">\u26a1 R\u0103spuns rapid \u2014 Ce este Invokana?<\/h3>\n<p style=\"margin:0;\"><strong>Invokana<\/strong> este o marc\u0103 a <strong>canagliflozin<\/strong> (100 mg sau 300 mg), un <strong>inhibitor SGLT-2<\/strong> (\u201cgliflozin\u0103\u201d) utilizat pentru <strong>diabet zaharat de tip 2, insuficien\u021b\u0103 cardiac\u0103 \u0219i boal\u0103 renal\u0103 cronic\u0103 (BRC). Ac\u021bioneaz\u0103 prin blocarea reabsorb\u021biei glucozei \u00een rinichi, determin\u00e2nd eliminarea a 70\u201390 g de glucoz\u0103 pe zi prin urin\u0103. Acest proces scade nivelul glucozei din s\u00e2nge independent de insulin\u0103, produce o pierdere \u00een greutate de 2\u20133 kg, sc\u0103derea tensiunii arteriale cu 3\u20135 mmHg \u0219i \u2014 \u00een mod unic printre antidiabetice \u2014 reduce num\u0103rul de spitaliz\u0103ri pentru insuficien\u021b\u0103 cardiac\u0103 \u0219i \u00eencetine\u0219te progresia BRC la pacien\u021bii cu sau f\u0103r\u0103 diabet. Reducere HbA1c: 0,6\u20130,9 puncte procentuale. Doz\u0103: 100 mg o dat\u0103 pe zi \u00eenainte de prima mas\u0103 a zilei. Se poate cre\u0219te la 300 mg\/zi dac\u0103 controlul glicemic nu este adecvat \u0219i eGFR este &gt; 60. Pentru indica\u021biile BRC\/CV: 100 mg\/zi.<\/strong>. Nu provoac\u0103 hipoglicemie. <strong>ca monoterapie. Riscuri principale: mugur\u0103 genital (frecvent, u\u0219oar\u0103), infec\u021bie urinar\u0103, cetoacidoz\u0103 diabetic\u0103 rar\u0103 (uneori cu glucoz\u0103 aproape normal\u0103 \u2014 \u201eDKA euglicemic\u0103\u201d) \u0219i deple\u021bie volumic\u0103. Evita\u021bi \u00een diabetul zaharat de tip 1.<\/strong> Ce este Invokana?.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate <a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">ale clien\u021bilor<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Medicamentele noastre generice sunt procurate de la produc\u0103tori certifica\u021bi WHO-GMP \u0219i expediate la nivel mondial \u00een ambalaje discrete \u0219i simple \u2014 f\u0103r\u0103 denumirea medicamentului pe exteriorul coletului. Pl\u0103\u021bile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de pl\u0103\u021bi cu card reglementat \u2014 niciodat\u0103 \u201cMedsBase\u201d sau numele vreunui medicament). Accept\u0103m \u0219i criptomonede \u0219i transferuri bancare SEPA. Fiecare comand\u0103 este sus\u021binut\u0103 de Politica noastr\u0103 de Asigurare pentru Relivrare.<\/p>\n<h2 class=\"wp-block-heading\">Invokana este un inhibitor oral SGLT-2 (cotransportorul 2 de sodiu-glucoz\u0103) care con\u021bine<\/h2>\n<p>(100 mg sau 300 mg), fabricat de Janssen \/ Johnson &amp; Johnson. Disponibil \u00een cutii de 30, 60, 90 sau 180 de comprimate. Este aprobat pentru: <strong>canagliflozin<\/strong> Diabet zaharat de tip 2 \u2014 pentru control glicemic, de obicei ca terapie adjunct\u0103 la metformin\u0103 sau ca linie a doua<\/p>\n<ul>\n<li>Insuficien\u021b\u0103 cardiac\u0103 \u2014 at\u00e2t cu frac\u021bie de ejec\u021bie redus\u0103 (HFrEF), c\u00e2t \u0219i p\u0103strat\u0103 (HFpEF), indiferent de prezen\u021ba diabetului<\/li>\n<li>Boal\u0103 renal\u0103 cronic\u0103 \u2014 pentru \u00eencetinirea progresiei, cu sau f\u0103r\u0103 diabet<\/li>\n<li>canagliflozina a fost aprobat\u0103 pentru prima dat\u0103 \u00een 2013 (marca original\u0103: Invokana, Janssen \/ Johnson &amp; Johnson). Este una dintre cele mai importante clase de antidiabetice din ultimul deceniu, deoarece acela\u0219i medicament trateaz\u0103 simultan trei dintre cele mai frecvente complica\u021bii pe termen lung ale diabetului.<\/li>\n<\/ul>\n<p>Cum func\u021bioneaz\u0103 Invokana?.<\/p>\n<h2 class=\"wp-block-heading\">How Does Invokana Work?<\/h2>\n<p>Rinichii s\u0103n\u0103to\u0219i filtreaz\u0103 180 g de glucoz\u0103 pe zi prin glomeruli \u0219i reabsorb aproape toat\u0103 \u00eenapoi \u00een circula\u021bia sanguin\u0103 prin transportorul SGLT-2 din tubul proximal. \u00cen diabet, aceast\u0103 reabsorb\u021bie este de fapt <em>reglat\u0103 \u00een sus<\/em> \u2014 organismul re\u021bine mai mult\u0103 glucoz\u0103 tocmai atunci c\u00e2nd ar trebui s\u0103 elimine o parte.<\/p>\n<p>canagliflozin blocheaz\u0103 selectiv SGLT-2, determin\u00e2nd excre\u021bia a 70\u201390 g de glucoz\u0103 pe zi \u00een urin\u0103. Acest lucru:<\/p>\n<ul>\n<li><strong>Scade glicemia cu aproximativ 30\u201350 mg\/dL<\/strong> \u2014 independent de insulin\u0103<\/li>\n<li><strong>Reduce greutatea cu 2\u20133 kg<\/strong> \u2014 pierderea de glucoz\u0103 prin urin\u0103 echivaleaz\u0103 cu ~280\u2013320 kcal\/zi<\/li>\n<li><strong>Reduce tensiunea arterial\u0103 sistolic\u0103 cu 3\u20135 mmHg<\/strong> \u2014 par\u021bial prin diurez\u0103 osmotic\u0103, par\u021bial prin alte c\u0103i<\/li>\n<li><strong>Reduce presiunea intraglomerular\u0103<\/strong> \u2014 \u00eencetinind progresia BCR<\/li>\n<li><strong>\u00cembun\u0103t\u0103\u021be\u0219te metabolismul energetic cardiac<\/strong> \u2014 contribuind la beneficiile \u00een insuficien\u021b\u0103 cardiac\u0103<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Beneficii cardiovasculare, \u00een insuficien\u021b\u0103 cardiac\u0103 \u0219i renal\u0103<\/h2>\n<p>canagliflozin are un set de date de studii clinice neobi\u0219nuit de puternic:<\/p>\n<ul>\n<li><strong>Programul CANVAS (2017)<\/strong> \u2014 a redus MACE cu 3 puncte la pacien\u021bii cu diabet zaharat tip 2 \u0219i risc cardiovascular ridicat.<\/li>\n<li>A redus spitaliz\u0103rile pentru insuficien\u021b\u0103 cardiac\u0103 \u00een CANVAS \u0219i CREDENCE.<\/li>\n<li><strong>CREDENCE (2019)<\/strong> \u2014 reducere de 30% a unui compus care include boal\u0103 renal\u0103 \u00een stadiu terminal, dublarea creatininei sau deces renal\/CV. Oprit \u00eenainte de termen datorit\u0103 eficacit\u0103\u021bii. Studiu de referin\u021b\u0103 pentru SGLT-2 \u00een BCR diabetic.<\/li>\n<\/ul>\n<p>Aceste studii au schimbat practica: inhibitorii SGLT-2 sunt acum recomanda\u021bi pentru orice pacient cu diabet zaharat tip 2 care are boli cardiovasculare stabilite, insuficien\u021b\u0103 cardiac\u0103 sau BCR \u2014 indiferent de HbA1c.<\/p>\n<h2 class=\"wp-block-heading\">Doza \u0219i administrare<\/h2>\n<p><strong>Doza standard:<\/strong> 100 mg o dat\u0103 pe zi \u00eenainte de prima mas\u0103 a zilei. Titra\u021bi la 300 mg\/zi dac\u0103 controlul glicemic nu este adecvat \u0219i eGFR este &gt; 60. Pentru indica\u021bii BCR\/CV: 100 mg\/zi.<\/p>\n<ul>\n<li>Doza\u021bie o dat\u0103 pe zi; momentul poate fi fixat \u00eentr-o rutin\u0103.<\/li>\n<li>Nu este necesar s\u0103 fie luat cu alimente (cu excep\u021bia cazurilor men\u021bionate pentru canagliflozin).<\/li>\n<li>Omite\u021bi o doz\u0103 \u2014 lua\u021bi-o dac\u0103 v\u0103 aminti\u021bi \u00een decurs de 12 ore; altfel s\u0103ri\u021bi peste.<\/li>\n<li><strong>Invokana\/canagliflozin:<\/strong> ini\u021biere p\u00e2n\u0103 la eGFR 30 mL\/min\/1,73 m\u00b2; continua\u021bi p\u00e2n\u0103 la dializ\u0103. Limita\u021bi doza la 100 mg\/zi dac\u0103 eGFR &lt; 60.<\/li>\n<li>Nu ini\u021bia\u021bi \u00een timpul unei boli acute cu deshidratare (risc de AKI \u0219i DKA euglicemic).<\/li>\n<li><strong>Reguli pentru zilele de boal\u0103:<\/strong> \u00eentrerupe\u021bi inhibitorul SGLT-2 \u00een timpul oric\u0103rei boli acute cu v\u0103rs\u0103turi, diaree sau aport oral redus. Relua\u021bi c\u00e2nd m\u00e2nca\u021bi normal.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Efecte Secundare<\/h2>\n<p><strong>Frecvente:<\/strong><\/p>\n<ul>\n<li><strong>Infec\u021bii micotice genitale (mugur)<\/strong> \u2014 p\u00e2n\u0103 la 10% dintre utilizatori, \u00een special femei. U\u0219or de tratat cu antifungice.<\/li>\n<li><strong>Infec\u021bii ale tractului urinar<\/strong> \u2014 exces moderat; majoritatea sunt cistite simple.<\/li>\n<li>M\u0103rire a frecven\u021bei urin\u0103rii (poliurie), deshidratare u\u0219oar\u0103, ame\u021beli la ridicare (hipotensiune postural\u0103) \u2014 mai ales \u00een primele 2 s\u0103pt\u0103m\u00e2ni.<\/li>\n<li>Cre\u0219tere moderat\u0103 a colesterolului LDL (de obicei &lt; 0,2 mmol\/L).<\/li>\n<\/ul>\n<p><strong>Pu\u021bin frecvente, dar importante:<\/strong><\/p>\n<ul>\n<li><strong>Cetoacidoz\u0103 diabetic\u0103 (DKA)<\/strong> \u2014 rar\u0103 (&lt; 0,1% pe an) dar poate ap\u0103rea la glicemie aproape normal\u0103 (\u201cDKA euglicemic\u0103\u201d). Factori de risc: aport redus de carbohidra\u021bi, boal\u0103 acut\u0103, interven\u021bie chirurgical\u0103, reducerea dozei de insulin\u0103. Simptome: grea\u021b\u0103, v\u0103rs\u0103turi, dureri abdominale, respira\u021bie ad\u00e2nc\u0103. <strong>\u00centrerupe\u021bi medicamentul \u0219i c\u0103uta\u021bi \u00eengrijire medical\u0103 urgent\u0103.<\/strong><\/li>\n<li><strong>Deple\u021bie de volum<\/strong> \u2014 risc mai mare la adul\u021bii \u00een v\u00e2rst\u0103, cei care iau diuretice sau au tensiune arterial\u0103 sc\u0103zut\u0103.<\/li>\n<li><strong>Leziune renal\u0103 acut\u0103<\/strong> \u2014 de obicei pre-renal\u0103 \u00een contextul deshidrat\u0103rii; reversibil\u0103 la \u00eentreruperea administr\u0103rii medicamentului.<\/li>\n<li><strong>Gangrena Fournier<\/strong> \u2014 infec\u021bie necrozant\u0103 perineal\u0103 extrem de rar\u0103; constituie urgen\u021b\u0103 medical\u0103.<\/li>\n<li>Studiul CANVAS a demonstrat o <strong>dublare a riscului de amputare a membrelor inferioare<\/strong> (\u00een special degete\/picior). Semnalul nu a fost reprodus \u00een studiul CREDENCE sau \u00een datele ulterioare din practica real\u0103, iar FDA a eliminat avertismentul s\u0103u \u00eencadrat \u00een 2020. Cu toate acestea, medicii evalueaz\u0103 de obicei prezen\u021ba bolii arteriale periferice \u0219i evit\u0103 canagliflozina la pacien\u021bii cu antecedente de amputare sau ulcere la picioare.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interac\u021biuni medicamentoase<\/h2>\n<ul>\n<li><strong>Diuretice (\u00een special diureticele de ans\u0103 \u0219i tiazidice)<\/strong> \u2014 pierdere de volum aditiv\u0103; se poate lua \u00een considerare reducerea dozei de diuretic la ini\u021bierea tratamentului.<\/li>\n<li><strong>Insulin\u0103 \u0219i sulfoniluree<\/strong> \u2014 efect hipoglicemiant aditiv; poate fi necesar\u0103 reducerea dozelor pentru a evita hipoglicemia.<\/li>\n<li><strong>Litiu<\/strong> \u2014 pierderea urinar\u0103 crescut\u0103 poate cre\u0219te nivelul de litiu.<\/li>\n<li><strong>Rifampicin\u0103<\/strong> \u2014 reduce nivelul inhibitorilor SGLT-2; poate fi necesar\u0103 o doz\u0103 mai mare.<\/li>\n<li><strong>Antihipertensive<\/strong> \u2014 sc\u0103dere aditiv\u0103 a tensiunii arteriale; se recomand\u0103 monitorizarea ame\u021belilor.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Cine nu ar trebui s\u0103 ia Invokana?<\/h2>\n<ul>\n<li>Diabet zaharat de tip 1 (cu excep\u021bia cazurilor off-label \u0219i supravegheat de specialist)<\/li>\n<li>Cetoacidoz\u0103 diabetic\u0103 \u2014 istoric recent sau actual<\/li>\n<li>Insuficien\u021b\u0103 renal\u0103 sever\u0103 sub pragul de ini\u021biere<\/li>\n<li>Boal\u0103 renal\u0103 \u00een stadiu terminal la dializ\u0103 (opri\u021bi odat\u0103 ce \u00eencepe dializa pentru empagliflozin\u0103; dapagliflozina poate fi continuat\u0103 conform unor protocoale)<\/li>\n<li>Deple\u021bie sever\u0103 de volum sau hipotensiune<\/li>\n<li>Sarcina \u0219i al\u0103ptarea \u2014 date limitate; evita\u021bi<\/li>\n<li>Hipersensibilitate cunoscut\u0103 la inhibitorii SGLT-2<\/li>\n<li>Canagliflozin\u0103: amputare anterioar\u0103 a membrelor inferioare sau ulcer activ la picior (relativ)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Depozitare<\/h2>\n<p>P\u0103stra\u021bi Invokana sub 30\u00b0C \u00eentr-un loc uscat, \u00een blisterul original. Depozita\u021bi \u00een afara razei de ac\u021biune a copiilor.<\/p>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3 class=\"wp-block-heading\">Este Invokana acela\u0219i lucru cu canagliflozin?<\/h3>\n<p>Da \u2014 Invokana con\u021bine canagliflozin ca principiu activ. Autorit\u0103\u021bile de reglementare cer bioechivalen\u021b\u0103, astfel \u00eenc\u00e2t efectul clinic este acela\u0219i la aceea\u0219i doz\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Este canagliflozin sigur \u2014 ce spune\u021bi despre riscul de amputare?<\/h3>\n<p>Semnalul de amputare a ap\u0103rut din programul CANVAS (risc absolut 6,3 vs 3,4 la 1000 de ani-pacient). Semnalul nu a fost observat \u00een CREDENCE sau \u00een majoritatea studiilor din lumea real\u0103, iar FDA a eliminat avertismentul s\u0103u \u00een caset\u0103 \u00een 2020. Majoritatea clinicienilor consider\u0103 acum canagliflozin sigur pentru pacien\u021bii f\u0103r\u0103 amputare anterioar\u0103, ulcer la picior activ sau boal\u0103 arterial\u0103 periferic\u0103 sever\u0103. Verific\u0103rile picioarelor \u0219i igiena \u00eenc\u0103l\u021b\u0103mintei sunt recomandate la orice inhibitor SGLT-2.<\/p>\n<h3 class=\"wp-block-heading\">Va ajuta Invokana la pierderea \u00een greutate?<\/h3>\n<p>Da, modest \u2014 de obicei o pierdere de 2\u20133 kg pe parcursul a 6\u201312 luni. Pierderea \u00een greutate se datoreaz\u0103 faptului c\u0103 rinichii t\u0103i elimin\u0103 70\u201390 g de glucoz\u0103 (~280\u2013320 kcal) pe zi \u00een urin\u0103. Este real\u0103, dar limitat\u0103 \u2014 nu v\u0103 a\u0219tepta\u021bi la efectele dramatice observate cu agonii\u0219tii receptorului GLP-1, cum ar fi semaglutida (Ozempic, Wegovy) sau tirzepatida (Mounjaro).<\/p>\n<h3 class=\"wp-block-heading\">Va sc\u0103dea Invokana tensiunea mea arterial\u0103?<\/h3>\n<p>Da \u2014 a\u0219tepta\u021bi-v\u0103 la o sc\u0103dere sistolic\u0103 de aproximativ 3\u20135 mmHg. Dac\u0103 lua\u021bi deja medicamente pentru tensiune arterial\u0103 \u0219i sunte\u021bi aproape de \u021bint\u0103, este posibil s\u0103 ave\u021bi nevoie de o reducere a dozei atunci c\u00e2nd \u00eencepe\u021bi s\u0103 lua\u021bi Invokana pentru a evita ame\u021belile.<\/p>\n<h3 class=\"wp-block-heading\">Poate Invokana provoca boli fungice sau infec\u021bii ale tractului urinar?<\/h3>\n<p>Da \u2014 boala fungic\u0103 genital\u0103 este cel mai frecvent efect secundar (p\u00e2n\u0103 la 10% dintre utilizatori, \u00een special femei). Este de obicei u\u0219oar\u0103 \u0219i u\u0219or de tratat cu antifungice topice orale. Infec\u021biile tractului urinar sunt pu\u021bin mai frecvente, dar de obicei simple. O igien\u0103 bun\u0103 ajut\u0103; majoritatea pacien\u021bilor nu trebuie s\u0103 \u00eentrerup\u0103 tratamentul.<\/p>\n<h3 class=\"wp-block-heading\">Pot lua Invokana dac\u0103 rinichii mei nu sunt \u00een regul\u0103?<\/h3>\n<p>Da \u2014 \u0219i, de fapt, inhibitorii SGLT-2 <em>protejeaz\u0103<\/em> rinichii \u00een BCR. Punctele de ini\u021biere difer\u0103 \u00een func\u021bie de molecul\u0103 (verifica\u021bi sec\u021biunea privind dozarea renal\u0103), dar odat\u0103 \u00eencepute, acestea sunt de obicei continuate p\u00e2n\u0103 la dializ\u0103, deoarece efectul protector renal persist\u0103 chiar \u0219i atunci c\u00e2nd efectul de sc\u0103dere a glucozei a disp\u0103rut.<\/p>\n<h3 class=\"wp-block-heading\">Ce trebuie s\u0103 fac \u00een zilele de boal\u0103 sau \u00eenainte de opera\u021bie?<\/h3>\n<p>Suspend\u0103 administrarea Invokana \u00een timpul oric\u0103rei afec\u021biuni acute cu deshidratare, v\u0103rs\u0103turi sau aport oral redus, precum \u0219i \u00een timpul interven\u021biilor chirurgicale majore sau al postului. Aceasta reduce riscul de cetoacidoz\u0103 diabetic\u0103 euglicemic\u0103 \u0219i leziune renal\u0103 acut\u0103. Relua\u021bi administrarea odat\u0103 ce alimenta\u021bia \u0219i hidratarea revin la normal.<\/p>\n<h3 class=\"wp-block-heading\">Unde pot cump\u0103ra Invokana online?<\/h3>\n<p>Pute\u021bi comanda Invokana (100 mg sau 300 mg) de la MedsBase \u00een cutii de 30, 60, 90 sau 180 de comprimate. Livr\u0103m \u00een \u00eentreaga lume, cu ambalaj discret \u0219i stocuri autentice certificate WHO-GMP de la produc\u0103tor.<\/p>\n<h2 class=\"wp-block-heading\">Medicamente \u00eenrudite pentru Diabet<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/jardiance-empagliflozin\/\">Jardiance \u2014 Empagliflozin\u0103 25 mg (Boehringer)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/forxiga-dapagliflozin\/\">Forxiga \u2014 Dapagliflozin\u0103 5\/10 mg (AstraZeneca)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/invokana-canagliflozin\/\">Invokana \u2014 Canagliflozin\u0103 100 mg (Janssen)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/glyxambi-empagliflozin\/\">Glyxambi \u2014 Combina\u021bie Empagliflozin\u0103 + Linagliptin\u0103<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/januvia\/\">Januvia \u2014 Sitagliptin\u0103 (alternativ\u0103 DPP-4)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/glycomet-sr\/\">Glycomet SR \u2014 Metformin cu eliberare prelungit\u0103<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/diabetes-medication\/\"><strong>Vizualiza\u021bi toate Medicamentele pentru Diabet<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:16px 20px;margin:24px 0;border-radius:4px;\"><strong>\u2695 Dezaprobare medical\u0103.<\/strong> Aceast\u0103 pagin\u0103 are doar scop informativ \u0219i nu \u00eenlocuie\u0219te sfatul medical al unui profesionist calificat \u00een domeniul s\u0103n\u0103t\u0103\u021bii. Inhibitorii SGLT-2 prezint\u0103 un risc mic dar serios de cetoacidoz\u0103 diabetic\u0103 euglicemic\u0103 \u0219i depletare volumic\u0103 \u2014 utiliza\u021bi \u00eentotdeauna sub \u00eendrumare medical\u0103, respect\u00e2nd regulile pentru zilele de boal\u0103.<\/div>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Alternative conexe<\/h3>\n<p>Alte produse din <strong>Afec\u021biuni cronice<\/strong> pe care clien\u021bii le vizualizeaz\u0103 de asemenea:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/simlo-5\/\">Simlo 5<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/anacin\/\">Anacin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/sertagress\/\">Sertagress<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/cosart\/\">Cosart<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/tenvir-af\/\">Tenvir AF<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Regleaz\u0103 nivelul zah\u0103rului din s\u00e2nge<br \/>\n\u2705 Reduce riscul de boli cardiace<br \/>\n\u2705 Promoveaz\u0103 <a title=\"Rybelsus o solu\u021bie eficient\u0103 pentru pierderea \u00een greutate\" href=\"https:\/\/medsbase.com\/ro\/rybelsus-an-effective-solution-for-weight-loss\/\">Pierdere \u00een greutate<\/a><br \/>\n\u2705 <a title=\"Cum s\u0103-\u021bi reduci tensiunea arterial\u0103\" href=\"https:\/\/medsbase.com\/ro\/how-to-lower-your-blood-pressure\/\">Scade tensiunea arterial\u0103<\/a><br \/>\n\u2705 \u00cembun\u0103t\u0103\u021be\u0219te s\u0103n\u0103tatea rinichilor<\/p>\n<p><span style=\"color: #999999;\">Invokana con\u021bine Canagliflozin<\/span><\/p>","protected":false},"featured_media":55131,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3230,3231],"product_tag":[3866,3867],"class_list":{"0":"post-55130","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-diabetes","9":"product_cat-diabetes-medication","10":"product_tag-canagliflozin","11":"product_tag-invokana","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/55130","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=55130"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/55131"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=55130"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=55130"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=55130"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=55130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}